Merck KGaA, Darmstadt, Germany, Announces New Sector CFO Healthcare 

Merck KGaA, Darmstadt, Germany, today announced that effective January 1, 2022, Jakob Hoppe will become Sector CFO Healthcare, reporting to Marcus Kuhnert ...

16 Nov 2021 | Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that effective January 1, 2022, Jakob Hoppe will become Sector CFO Healthcare, reporting to Marcus Kuhnert, Member of the Executive Board and Chief Financial Officer of Merck KGaA, Darmstadt, Germany. Hoppe will succeed Andreas Stickler who has decided to leave the company effective December 31, 2021 to continue his career outside of Merck KGaA, Darmstadt, Germany.

“I would like to wholeheartedly thank Andreas Stickler for his leadership and outstanding contributions to our company’s success. He has not only been a highly respected member of the Finance and Healthcare leadership teams and extremely seasoned expert in the field of financials, he also significantly contributed to the successful transformation of our Healthcare business”, said Marcus Kuhnert. “At the same time, I am particularly pleased that with Jakob Hoppe as new Sector CFO Healthcare one of our internal top talents will be promoted to a senior leadership position”, Kuhnert continued.

Andreas Stickler joined Merck KGaA, Darmstadt, Germany, in 2002 as financial controller for Europe as well as Oncology and since then held various, key-leadership positions. From 2008 to 2015, as Head of Group M&A, he drove major strategic acquisitions (e. g. Serono, Millipore, Sigma Aldrich), which were mission critical for future profitable growth of Merck KGaA, Darmstadt, Germany. In 2015, Andreas Stickler became Sector CFO Healthcare and took on additional responsibility as Head of Strategy, Business Development, Portfolio Management and Digital & Data in 2019.

Jakob Hoppe joined Merck KGaA, Darmstadt, Germany, in 2007 as Graduate Trainee in Finance. Since then, he held various positions of growing strategic relevance and impact within Group Finance; most recently as Head of Controlling, Marketing and Strategy Healthcare, where he also led the Immunology Franchise on an ad interim basis for over a year. In his new role, he will become a member of the CFO Council and Healthcare Executive Committee.


For more information, please contact Friederike Segeberg

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany, generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany, to Showcase Advances in the Science of Cancer

    Merck KGaA, Darmstadt, Germany, today announced new research from the company’s diverse oncology portfolio will be presented at ASCO 2024.